ABOUT THIS BOOK ◾ Reviews the current treatment recommendations for cutaneous melanoma and emerging treatment options based on recent clinical trials ◾ Images exemplify the disease and diagnostic and treatment algorithms, which will help readers achieve a strong grasp on tumor growth and patients' prognosis ◾ Highlighted take-home messages reinforce the most important points of each section, giving the reader a comprehensive review
Handbook of Cutaneous Melanoma is a concise review, which discusses epidemiology, pathogenesis, clinical features, diagnosis and staging, and current and emerging treatments for local and metastatic disease. The Handbook is heavily illustrated with diagnostic guides and treatment algorithms from Dr Schadendorf (which are supported by national and international guidelines), as well as numerous images from his practice to support the text. Busy healthcare professionals who want a quick review of diagnostic and staging guidelines as well as a summary of current therapies for cutaneous melanoma will benefit from this succinct guide.
Author Dirk Schadendorf MD is the Director of the Department of Dermatology at the University Hospital Essen, Germany. In his current role, Professor Schadendorf is currently involved in 31 clinical studies. He is the current president of the German DeCOG(Dermatologic Cooperative Oncology Group) and chair-elect of the well known EORTC Melanoma Group. He has a strong focus on translational research and has published more than 300 peer-reviewed papers. Coauthor Corinna Kochs MD is a resident at the Department of Dermatology, University Hospital Essen, Germany. From 2011–2013, she was involved in the development of the German Melanoma Guideline 2013, published by the German Guideline Program in Oncology, where her main responsibilities were the project coordination and methodology Coauthor Elisabeth Livingstone MD is Attending Physician at the Department of Dermatology, University Hospital Essen, Germany. Her main clinical and research activities are in the field of dermatooncology and cutaneous adverse events of new oncological substances. As sub-investigator, she has been involved in several phase II–III trials for melanoma and basal cell carcinoma.